Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab to radiotherapy;Étude prospective monocentrique de la toxicité et de l'efficacité du trastuzumab concomitant à la radiothérapie

Cancer/Radiotherapie

Volumn 17, Issue 3, 2013, Pages 183-190

  Jacob, J ^a   Belin, L ^a   Gobillion, A ^a   Daveau Bergerault, C ^a   Dendale, R ^a   Beuzeboc, P ^a   Campana, F ^a   Bollet, M A ^a   Fourquet, A ^a   Kirova, Y M ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Radiotherapy; Toxicity; Trastuzumab

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST FIBROSIS; CANCER RADIOTHERAPY; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; BREAST TUMOR; CHEMORADIOTHERAPY; DRUG EFFECT; ESOPHAGITIS; FEMALE; FIBROSIS; HEART STROKE VOLUME; LYMPHEDEMA; MASTECTOMY; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PAIN; PATHOLOGY; RADIATION DERMATITIS; RADIATION EXPOSURE; SEGMENTAL MASTECTOMY; SKIN; TELANGIECTASIA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMORADIOTHERAPY; ESOPHAGITIS; FEMALE; FIBROSIS; HUMANS; LYMPHEDEMA; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; RADIODERMATITIS; SKIN; STROKE VOLUME; TELANGIECTASIS;

EID: 84883022802     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2012.12.006     Document Type: Article

References (28)

1. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
2. Liang K., Lu Y., Jin W., Ang K.K., Milas L., Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2003, 2:1113-1120.
3. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
4. Dillman R.O. Perceptions of herceptin: a monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm 1999, 14:5-10.
5. Pietras R.J., Poen J.C., Gallardo D., Wongwipat P.N., Lee H.J., Slamon D.J. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999, 59:1347-1355.
6. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
7. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 2005, 353:1673-1684.
8. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
9. Untch M., Rezai M., Loibl S., Fasching P.A., Huober J., Tesch H., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010, 28:2024-2031.
10. Suter T.M., Cook-Burns N., Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004, 13:173-183.
11. Clarke M., Collins R., Darby S., Davies C., Elphinstone P., Evans E., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005, 366:2087-2106.
12. Kirova Y.M., Caussa L., Granger B., Savignoni A., Dendale R., Campana F., et al. Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy. Cancer Radiother 2009, 13:276-280.
13. Caussa L., Kirova Y.M., Gault N., Pierga J.Y., Savignoni A., Campana F., et al. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study. Eur J Cancer 2011, 47:65-73.
14. Campana F., Kirova Y.M., Rosenwald J.C., Dendale R., Vilcoq J.R., Dreyfus H., et al. Breast radiotherapy in the lateral decubitus position: a technique to prevent heart and lung irradiation. Int J Radiat Oncol Biol Phys 2005, 61:1348-1354.
15. Kirova Y.M., Campana F., Fournier-Bidoz N., Stilhart A., Dendale R., Bollet M.A., et al. Postmastectomy electron beam chest wall irradiation in women with breast cancer: a clinical step toward conformal electron therapy. Int J Radiat Oncol Biol Phys 2007, 69:1139-1144.
16. Hurkmans C.W., Borger J.H., Bos L.J., van der Horst A., Pieters B.R., Lebesque J.V., et al. Cardiac and lung complication probabilities after breast cancer irradiation. Radiother Oncol 2000, 55:145-151.
17. Kong F.M., Klein E.E., Bradley J.D., Mansur D.B., Taylor M.E., Perez C.A., et al. The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart dose for intact breast radiation. Int J Radiat Oncol Biol Phys 2002, 54:963-971.
18. Halyard M.Y., Pisansky T.M., Dueck A.C., Suman V., Pierce L., Solin L., et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009, 27:2638-2644.
19. Belkacémi Y., Gligorov J., Ozsahin M., Marsiglia H., De Lafontan B., Laharie-Mineur H., et al. Concurrent trastuzumab with adjuvant radiotherapy in HER-2 positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol 2008, 19:1110-1116.
20. Procter M., Suter T.M., de Azambuja E., Dafni U., van Dooren V., Muehlbauer S., et al. Longer-term assessment of trastuzumab-related cardiac events in the Herceptin Adjuvant (HERA) Trial. J Clin Oncol 2010, 28:3422-3428.
21. Shaffer R., Tyldesley S., Rolles M., Chia S., Mohamed I. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 2009, 90:122-126.
22. Belkacémi Y., Gligorov J. Concurrent trastuzumab - internal mammary node irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge" Radiother Oncol 2010, 94:119-120.
23. Alm El-Din M.A., Bellon J.R., Strom E.A., Bourgier C., Jagsi R., Niemierko A., et al. Radiation treatments may contribute to the development of cardiac dysfunction in breast cancer patients treated with chemotherapy and trastuzumab. Int J Radiat Oncol Biol Phys 2008, 72:S89-S90.
24. Ewer M.S., Vooletich M.T., Durand J.B., Woods M.L., David J.R., Valero V., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
25. Harris E.E., Correa C., Hwang W.T., Liao J., Litt H.I., Ferrari V.A., et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006, 24:4100-4106.
26. Taylor C.W., Nisbet A., McGale P., Darby S.C. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys 2007, 69:1484-1495.
27. Taylor C.W., McGale P., Povall J.M., Thomas E., Kumar S., Dodwell D., et al. Estimating cardiac exposure from breast cancer radiotherapy in clinical practice. Int J Radiat Oncol Biol Phys 2009, 73:1061-1068.
28. Cardinale D., Colombo A., Torrisi R., Sandri M.T., Civelli M., Salvatici M., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010, 28:3910-3916.